The cost-effectiveness body said in first draft guidance that evidence suggests Qarziba (dinutuximab beta) could increase overall survival compared with standard treatment, but there is ...
EUSA Pharma’s dinutuximab beta has gained European approval for its immunotherapy for children affected by a rare and devastating form of cancer, a move which exploits a gap in the market left ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback